Kuros Biosciences Expands into Extremities Markets
Kuros Biosciences announced its strategic expansion into the extremities markets, appointing Jantzen Cole as Vice President of Market Development, Extremities. The company is targeting a $1 billion addressable market with its MagnetOs technology, already approved for use beyond spine procedures. A dedicated Surgeon Advisory Board has been formed to guide clinical and commercial strategies, including renowned experts from leading medical institutions. The expansion leverages existing hospital approvals and infrastructure, building on the company's success in the spine market. Kuros will introduce its technology to foot and ankle surgeons via the Foot Innovate platform.
Kuros Biosciences ha annunciato la sua espansione strategica nel mercato degli arti, nominando Jantzen Cole come Vice Presidente dello Sviluppo del Mercato, Arti. L'azienda sta puntando a un mercato indirizzabile da 1 miliardo di dollari con la sua tecnologia MagnetOs, già approvata per l'uso oltre le procedure spinali. È stato creato un Comitato Consultivo di Chirurghi dedicato per guidare le strategie cliniche e commerciali, che comprende esperti rinomati provenienti da importanti istituzioni mediche. L'espansione sfrutta le approvazioni e l'infrastruttura ospedaliera esistenti, costruendo sul successo dell'azienda nel mercato spinale. Kuros presenterà la sua tecnologia ai chirurghi del piede e della caviglia tramite la piattaforma Foot Innovate.
Kuros Biosciences anunció su expansión estratégica en los mercados de extremidades, nombrando a Jantzen Cole como Vicepresidente de Desarrollo de Mercado, Extremidades. La compañía está apuntando a un mercado direccionable de 1 billón de dólares con su tecnología MagnetOs, ya aprobada para su uso más allá de los procedimientos de columna. Se ha formado un Consejo Asesor de Cirujanos dedicado para guiar las estrategias clínicas y comerciales, incluyendo a expertos reconocidos de instituciones médicas líderes. La expansión aprovecha las aprobaciones y la infraestructura hospitalaria existentes, construyendo sobre el éxito de la empresa en el mercado de la columna. Kuros presentará su tecnología a los cirujanos de pie y tobillo a través de la plataforma Foot Innovate.
Kuros Biosciences는 Jantzen Cole을 말초 시장 개발 부사장으로 임명하며 전략적 확장을 발표했습니다. 이 회사는 척추 수술을 넘어 사용할 수 있도록 이미 승인된 MagnetOs 기술을 통해 10억 달러의 시장을 목표로 하고 있습니다. 임상 및 상업 전략을 안내하기 위해 저명한 의료 기관의 전문가들로 구성된 외과 의사 자문 위원회가 설립되었습니다. 이번 확장은 기존 병원 승인 및 인프라를 활용하여 척추 시장에서 회사의 성공을 기반으로 하고 있습니다. Kuros는 Foot Innovate 플랫폼을 통해 발 및 발목 외과 의사에게 기술을 소개할 예정입니다.
Kuros Biosciences a annoncé son expansion stratégique sur les marchés des extrémités, en nommant Jantzen Cole au poste de vice-président du développement du marché, extrémités. L'entreprise vise un marché adressable de 1 milliard de dollars avec sa technologie MagnetOs, déjà approuvée pour une utilisation au-delà des procédures de colonne vertébrale. Un Conseil Consultatif de Chirurgiens dédié a été formé pour orienter les stratégies cliniques et commerciales, incluant des experts renommés d'institutions médicales de premier plan. L'expansion s'appuie sur les approbations et les infrastructures hospitalières existantes, s'appuyant sur le succès de l'entreprise sur le marché de la colonne vertébrale. Kuros présentera sa technologie aux chirurgiens du pied et de la cheville via la plateforme Foot Innovate.
Kuros Biosciences hat seine strategische Expansion in die Extremitätenmärkte angekündigt und Jantzen Cole zum Vice President für Marktentwicklung, Extremitäten ernannt. Das Unternehmen zielt mit seiner MagnetOs-Technologie, die bereits für Anwendungen über Wirbelsäulenverfahren hinaus genehmigt ist, auf einen adressierbaren Markt von 1 Milliarde Dollar. Ein eigens eingerichteter Ärztlicher Beirat wird gebildet, um klinische und kommerzielle Strategien zu lenken, darunter renommierte Experten führender medizinischer Einrichtungen. Die Expansion nutzt bestehende Krankenhausgenehmigungen und Infrastrukturen und baut auf dem Erfolg des Unternehmens im Wirbelsäulenmarkt auf. Kuros wird seine Technologie über die Plattform Foot Innovate an Fuß- und Sprunggelenkschirurgen einführen.
- Expansion into $1 billion addressable extremities market
- Three MagnetOs formulations already approved for use beyond spine procedures
- Leveraging existing hospital approvals and infrastructure
- Formation of expert Surgeon Advisory Board for market guidance
- Company anticipates strong financial performance for 2024
- None.
Commercial Highlights
Appointment of Jantzen Cole as Vice President of Market Development, Extremities, to drive the Company's acceleration beyond the spine market
Strategic expansion opens new addressable market opportunity estimated at
$1 billion Formation of a dedicated Surgeon Advisory Board to shape clinical and commercial strategies for MagnetOs TM in extremities markets
ZURICH, SWITZERLAND / ACCESSWIRE / November 19, 2024 / Kuros Biosciences ("Kuros"), a global leader in advanced bone healing technologies, today announced its strategic expansion into the extremities markets with the appointment of Jantzen Cole as Vice President of Market Development, Extremities, as well as the formation of a dedicated Surgeon Advisory Board (SAB).
With over two decades in the orthopedic and medical device fields, Mr. Cole brings extensive experience in product innovation, brand-building and strategic market development. His expertise is underscored by his most recent success as Vice President of Marketing at Artelon, a leading orthopedic solutions company, where he drove notable revenue growth and brand recognition in the ankle instability market leading up to a recent acquisition by Stryker.
Under Mr. Cole's leadership, Kuros will leverage its existing hospital approvals and established infrastructure, building on the Company's proven success in the spine market. With three of the MagnetOs formulations already indicated for use beyond spine procedures, this expansion opens a market opportunity with a total addressable market estimated at
To further support this expansion, Kuros has initiated a SAB of renowned experts to offer insights and guidance for the introduction of MagnetOs in the extremities markets. The initial board members include Greg Berlet, MD, FAOA, FRCS(C), Orthopedic Foot & Ankle Center, Westerville, Ohio; Peter Mangone, MD, FAAOS, Chief of Foot & Ankle Surgery, University of Pittsburgh Medical Center (UPMC), PA; and Carlos Sagebien, MD, FAAOS, Clinical Assistant Professor of Orthopaedics, Robert Wood Johnson University Hospital, New Brunswick, NJ. The development of this specialized advisory board will be instrumental in defining clinical applications and commercial strategies to best meet patient, surgeon and hospital needs.
Kuros will introduce its MagnetOs technology to foot and ankle surgeons via the Foot Innovate platform on Thursday, November 21 at 7:30pm ET. The Foot Innovate mission is education through the collaboration of expert medical professionals. This introduction will be led by Dr. Greg Berlet and Dr. Katherine Sage, Kuros Senior Vice President, Medical and Clinical Affairs. Together Dr. Berlet and Dr. Sage will explore the history, science and data supporting MagnetOs, as well as its clinical opportunity in foot and ankle (F&A) procedures. ( Register to attend ).
"We are thrilled to welcome Jantzen to the Kuros team. His extensive F&A expertise and proven success in launching transformative medical technologies align seamlessly with our vision," said Chris Fair, Chief Executive Officer of Kuros Biosciences. "With our robust clinical data and support of our newly founded SAB, Kuros is well-positioned to expand globally beyond spine. We anticipate finishing 2024 with strong financial performance, strengthening our position as a premier advanced bone healing company across multiple musculoskeletal markets."
For further information, please contact:
Kuros Biosciences AG |
|
About MagnetOs
MagnetOs is a bone graft like no other: thanks to its NeedleGrip TM surface technology, it grows bone even in soft tissues. This surface technology provides traction for our body's vitally important ‘pro-healing' immune cells (M2 macrophages). This in turn, unlocks previously untapped potential to stimulate stem cells - and form new bone throughout the graft. The growing body of science behind NeedleGrip is called osteoimmunology. But for surgeons and their patients it means one thing: a more predictable fusion. *†‡1-5
Indications statement
Please refer to the instructions for use for your local region for a full list of indications, contraindications, warnings and precautions.
About Kuros Biosciences
Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company's first commercial product, MagnetOs TM , is a unique advanced bone graft that has already been used across four continents. For more information on the company, its products and pipeline, visit kurosbio.com .
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.
*Results from in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit kurosbio.com.
† MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft.
‡ MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion.
1. Van Dijk,et al. eCM. 2021; 41:756-73.
2. Duan, et al. eCM. 2019; 37:60-73.
3. Van Dijk, et al. Clin Spine Surg. 2020;33(6): E276-E287.
4. Van Dijk, et al. JOR Spine. 2018; e1039.
5. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090.
SOURCE: Kuros Biosciences AG
View the original press release on accesswire.com
FAQ
What is Kuros Biosciences' new market expansion strategy for CSBTF?
Who did Kuros Biosciences appoint as VP of Market Development, Extremities for CSBTF?
What is the size of the new market opportunity for Kuros Biosciences CSBTF?
When will Kuros Biosciences introduce MagnetOs to foot and ankle surgeons?
